3D Bioprinting Market Overview

Global 3D Bioprinting market was estimated at USD 1.01 billion in 2021, and is anticipated to reach USD 3.14 billion by 2028, growing at a CAGR of 17.64%.

3D bioprinting has been an emanate field represented by various biologically applied deposition and assembling systems, that includes direct writing, photolithography, microstamping, extrusion, laser writing, electro-printing, stereolithography, microfluidics, and inkjet deposition. Healthcare is one of the major applications where 3D bioprinting is bringing a significant change. This is primarily due to the increasing investments in these applications, such as model and organ prototyping and production across the globe, and growing innovations in healthcare through 3D printing. The company has been creating its name by offering pharmaceutical companies with their exVive3D Liver Tissue for medicine toxicity testing. They had also merged with various leading companies, including Merck and L’Oréal in the health space and are preparing on launching their exVive3D Kidney Tissue product. With the 3D bioprinting process, an organ can be designed using modelling software, and then printed with biomaterials, such as hydrogels and polymers, in addition to the patient’s cells.

The need for organ transplantation across the world has increased in recent years, owing to increasing diseases requiring transplants. According to latest NHS (National Health Service) figures, the average time a person spends on the waiting for a kidney transplant is around 2 and a half to 3 years. Some leading players are also increasingly exploring 3D bioprinting, as it also reduces the risks associated with anesthesia during long surgeries and helps improve healthcare services. For instance, In August 2019, different scientists created a first-of-its-kind method which is utilized to bring the field of tissue engineering one step closer to being able to 3D print a full-sized, adult human heart.

COVID-19 Impact Analysis of 3D Bioprinting Market 

The 3D printing market will indicate a contraction in potential revenue that could be generated. For instance, the reduced in expected revenue for 2027 is expected to be USD 6.3, and, this is far good than what many other industries would be observing now as a result of the different implications of COVID-19. The motivating fact for the 3D printing industry, however, is that the return to double-digit positive rates is expected to take place as possible as next year, which is especially attractive for new entrants planning on entering the market in the upcoming years.

Market Dynamics and Factors

Drivers:

Increasing Geriatric Population

The maturating population is poised as one of the most significant social transformations of the twenty-first century. Globally, the population aged 60 or above is growing faster than all younger age groups. According to the data by the World Population Prospects, the number of people aged 60 years or above is expected to be more than double by 2050, and it is growing faster than the age groups consisting of youth, worldwide. This trend has an increasing demand for caregivers providing 24-hour care, not only at hospitals or nursing homes but also at apartments and private homes. Health-related issues, such as incidences of gangrene that are related to diabetes, osteoarthritis, and peripheral vascular diseases, are more common among the geriatric population. As they have lower immunity levels and are prone to neurological diseases, cardiac problems, cancers, and spinal injuries, therefore their growth is a high impact-rendering driver for the growth of 3D bioprinting market.

Increasing Investments In R&D

The cost of researching new therapies has steadily mounted over the past few years. If the current drug discovery process remains unchanged, companies’ returns on these investments will continue to shrink. In light of growing costs, some organizations have overcome or even eliminated their R&D departments, opting to contract these services instead. Due to this, 3D bioprinting is being adopted by the companies to simplify the research processes in the healthcare sector. Companies like Organovo have potentially transformed the R&D process through 3D bioprinting. The company’s model can be used during research and development for toxicology and efficacy testing. The delivery of bio-printed tissues (like Organovo’s human liver model) and research into other tissues has the potential to stimulating the drug discovery process and overcome research and development costs.

Restraints:

Organ printing is a computer-aided method, in which, cells and cell-laden biomaterials are incorporated in order to a blueprint model and serve as building blocks that are further assembled into 3D constructs and matured toward functional organ formation. To successfully employ organ printing at the clinical level, robust automated protocols and procedures should be established. The process of bioprinting undergoes program printing stage, organ printing stage, and post organ printing stage.

In organ printing stage, there is a bioprinting vascular network stage, where to print at clinically relevant volumes, robust technologies and protocols should be developed to enable printing of vascular constructs in multiple scales, ranging from arteries and veins down to capillaries. Because it is difficult to print submicron scale capillaries using current bioprinting technologies, one alternative strategy can be to print a microvasculature network and rely on capillary network formation through angiogenesis. Thus, bio-printed organs will present challenges to organ transplants being complex.

The bioprinting methodology requires to rise speed and resolution and should be united with a wide spectrum of biocompatible materials. Biggest resolution will authorize better interaction and manage in the 3D microenvironment.

Additionally, despite the daunting challenges that have been blocking the path toward the first functional 3D-printed organ, research areas are yielding new innovations every year as the academics and medical technology industry is working toward overcoming various barriers, that includes faster and finer bioprinters, limited options for biomaterials, maintaining soft material shape, mimicking natural vasculature, among others.

Opportunities:

Growing Demand for Regenerative Medicine and Stem Cell Research

Growing stem cell research activities and financial support from various public-private organizations are turning the growth of the stem cell and regenerative medicine industry over the globe. A supportive regulatory environment in emerging economies, the presence of a large number of stem cell product pipelines, and applications of regenerative medicine in treating diseases are the prime factors contributing to the growing adoption of stem cell and regenerative medicine globally. 3D bioprinting is utilized in numerous applications in regenerative medicine. It is applied in the creation of body parts such as cartilage, heart, and liver, among other organs, for the treatment of various disease conditions. In addition, stem cells are also utilized on a major scale for bioprinting various bones and tissues. These cells can modify easily to growth factors and develop into the required 3D structures.

Market Segmentation

Segmentation Insights

Based on Technology, Syringe/Extrusion Bioprinting dominated the market, with 36.99% market share in 2020. Magnetic Levitation Bioprinting is expected to witnessed the highest CAGR, of 22.72% over the forecast period.

Based on Application, Drug Testing and Development held the largest market share, of 38.04%, in 2020, while Regenerative Medicine is expected to witnessed the highest CAGR of 25.43% respectively.

Regional Analysis

Based on Geography, North America held the largest market share, of 46.76%, in 2020, while Asia-Pacific is expected to witnessed the highest CAGR, of 20.66% respectively.

North America region accounted the largest share of the market during forecast period owing to increasing incorporation of IT into the healthcare industry is anticipated to growth the 3D bioprinting market size in this region. In addition, the growing adoption of 3D bioprinting for the production of medical products is also anticipated to contribute to market growth.

Asia-Pacific region is accounted the major share in the market for 3D bioprinting after North America, owing to a strong established customer base that will turn surge for 3D bioprinting, huge scope of 3D printing in medical services, growing R&D for 3D printing, and government assistance and tax incentives. The growing demand for organ transplantation, rapid mergers and collaborations to increase the market share of the Europe region.

Increasing geriatric population and growing chronic illness accompanied by shortage of adequate organ donors are anticipated to boost Latin America 3D bioprinting market over the forecast period. In Middle East and Africa 3D bioprinting market, main revenue generating nations such as UAE, South Africa and Saudi Arabia and growing awareness about benefits such as adaptability and availability of adequate organs for transplant together with growing development in pharmaceutical and biotechnology would turn the market growth. 

Key Players Insights

Dimension Inx has signed a distribution agreement with Advanced Solutions Life Sciences (ASLS), to offer Dimension Inx’s bioprinting materials to clients around the globe. The company’s materials are part of its proprietary 3D-Painting platform and can be used for a range of hard and soft tissue bio fabrication applications. It contains Hyperelastic Bone and 3D-Graphene, and others.

The market is viewing strategic collaborations and mergers as a lucrative path toward the expansion of the market presence, by leveraging the various skills and expertise of the other players in the market. For instance, in December 2019, CELLINK, a Swedish 3D bioprinter manufacturer merged with microgravity producer, Made in Space., with the aim to identify 3D bioprinting development opportunities for the International Space Station (ISS).

The primarily increasing bioprinting applications include 3D bio-printed tissue and hair follicles, as they are very important to cosmetics companies, especially in Europe, where animal testing for cosmetics was banned in 2013. For a cosmetic company, the driver will be the capacity to economically and ethically test products over varying skin types, for more proper results.

The collaboration between cosmetic companies and the studied market vendors is also gaining traction over the past few years. The cosmetic giant L’Oreal signed a research agreement with French biotech company Poietis, to bioprint follicles capable of growing hair.

Key Industry Developments

May 2021 – A team of University of Alberta researchers announced that they have discovered a way to use 3D bioprinting technology in order to create custom shaped cartilage for usage in surgical procedures. The work primarily focuses to make it easier for the surgeons to safely restore the features of skin cancer patients living with nasal cartilage defects after the surgery. The scientist made usage of a specially created hydrogel, which is a material same to Jell-O that could be added with cells harvested from a patient and then can be printed in a particular shape captured along with 3-D imaging.

Mar 2021 – A POSTECH research group declared that they have succeeded in producing an artificial lung model using 3D printing technology. Professor Sungjune Jung from the Department of Materials Science and Engineering, and Professor Joo-Yeon Yoo along with Ph.D. student Dayoon Kang from the Department of Life Sciences at POSTECH passed in creating a 3D lung model containing a variety of human alveolar cell lines applying inkjet bioprinting methodology.

Players Covered in 3D Bioprinting market are :

• ARCAM AB (GE Company)
• Cyfuse Biomedical KK
• RegenHU SA
• 3D Systems Corporation
• Aspect Biosystems Ltd
• GeSIM GmbH
• Cellink AB
• Envision TEC GmbH
• Organovo Holdings Inc.
• Stratasys Ltd
• REGEMAT 3D
• 3D Bioprinting Solutions and Other Major Players.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Technology
 3.2 By Application
 3.3 By End Users

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: 3D Bioprinting Market by Technology
 5.1 3D Bioprinting Market Overview Snapshot and Growth Engine
 5.2 3D Bioprinting Market Overview
 5.3 Extrusion based
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2016-2028F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Extrusion based: Grographic Segmentation
 5.4 Inkjet-based
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2016-2028F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Inkjet-based: Grographic Segmentation
 5.5 Laser-assisted
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size (2016-2028F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Laser-assisted: Grographic Segmentation
 5.6 Others
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size (2016-2028F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Others: Grographic Segmentation

Chapter 6: 3D Bioprinting Market by Application
 6.1 3D Bioprinting Market Overview Snapshot and Growth Engine
 6.2 3D Bioprinting Market Overview
 6.3 Tissue Engineering
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2016-2028F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Tissue Engineering: Grographic Segmentation
 6.4 Regenerative Medicine
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2016-2028F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Regenerative Medicine: Grographic Segmentation
 6.5 Organ & Drug Printing
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2016-2028F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Organ & Drug Printing: Grographic Segmentation
 6.6 Toxicology Screening
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size (2016-2028F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Toxicology Screening: Grographic Segmentation
 6.7 Others
  6.7.1 Introduction and Market Overview
  6.7.2 Historic and Forecasted Market Size (2016-2028F)
  6.7.3 Key Market Trends, Growth Factors and Opportunities
  6.7.4 Others: Grographic Segmentation

Chapter 7: 3D Bioprinting Market by End Users
 7.1 3D Bioprinting Market Overview Snapshot and Growth Engine
 7.2 3D Bioprinting Market Overview
 7.3 Research Organizations & Academic Institutes
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size (2016-2028F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Research Organizations & Academic Institutes: Grographic Segmentation
 7.4 Biopharmaceutical companies
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size (2016-2028F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Biopharmaceutical companies: Grographic Segmentation
 7.5 Hospitals
  7.5.1 Introduction and Market Overview
  7.5.2 Historic and Forecasted Market Size (2016-2028F)
  7.5.3 Key Market Trends, Growth Factors and Opportunities
  7.5.4 Hospitals: Grographic Segmentation

Chapter 8: Company Profiles and Competitive Analysis
 8.1 Competitive Landscape
  8.1.1 Competitive Positioning
  8.1.2 3D Bioprinting Sales and Market Share By Players
  8.1.3 Industry BCG Matrix
  8.1.4 Ansoff Matrix
  8.1.5 3D Bioprinting Industry Concentration Ratio (CR5 and HHI)
  8.1.6 Top 5 3D Bioprinting Players Market Share
  8.1.7 Mergers and Acquisitions
  8.1.8 Business Strategies By Top Players
 8.2 ARCAM AB (GE COMPANY)
  8.2.1 Company Overview
  8.2.2 Key Executives
  8.2.3 Company Snapshot
  8.2.4 Operating Business Segments
  8.2.5 Product Portfolio
  8.2.6 Business Performance
  8.2.7 Key Strategic Moves and Recent Developments
  8.2.8 SWOT Analysis
 8.3 CYFUSE BIOMEDICAL KK
 8.4 REGENHU SA
 8.5 3D SYSTEMS CORPORATION
 8.6 ASPECT BIOSYSTEMS LTD
 8.7 GESIM GMBH
 8.8 CELLINK AB
 8.9 ENVISION TEC GMBH
 8.10 ORGANOVO HOLDINGS INC.
 8.11 STRATASYS LTD
 8.12 REGEMAT 3D
 8.13 3D BIOPRINTING SOLUTIONS
 8.14 OTHER MAJOR PLAYERS

Chapter 9: Global 3D Bioprinting Market Analysis, Insights and Forecast, 2016-2028
 9.1 Market Overview
 9.2 Historic and Forecasted Market Size By Technology
  9.2.1 Extrusion based
  9.2.2 Inkjet-based
  9.2.3 Laser-assisted
  9.2.4 Others
 9.3 Historic and Forecasted Market Size By Application
  9.3.1 Tissue Engineering
  9.3.2 Regenerative Medicine
  9.3.3 Organ & Drug Printing
  9.3.4 Toxicology Screening
  9.3.5 Others
 9.4 Historic and Forecasted Market Size By End Users
  9.4.1 Research Organizations & Academic Institutes
  9.4.2 Biopharmaceutical companies
  9.4.3 Hospitals

Chapter 10: North America 3D Bioprinting Market Analysis, Insights and Forecast, 2016-2028
 10.1 Key Market Trends, Growth Factors and Opportunities
 10.2 Impact of Covid-19
 10.3 Key Players
 10.4 Key Market Trends, Growth Factors and Opportunities
 10.4 Historic and Forecasted Market Size By Technology
  10.4.1 Extrusion based
  10.4.2 Inkjet-based
  10.4.3 Laser-assisted
  10.4.4 Others
 10.5 Historic and Forecasted Market Size By Application
  10.5.1 Tissue Engineering
  10.5.2 Regenerative Medicine
  10.5.3 Organ & Drug Printing
  10.5.4 Toxicology Screening
  10.5.5 Others
 10.6 Historic and Forecasted Market Size By End Users
  10.6.1 Research Organizations & Academic Institutes
  10.6.2 Biopharmaceutical companies
  10.6.3 Hospitals
 10.7 Historic and Forecast Market Size by Country
  10.7.1 U.S.
  10.7.2 Canada
  10.7.3 Mexico

Chapter 11: Europe 3D Bioprinting Market Analysis, Insights and Forecast, 2016-2028
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Technology
  11.4.1 Extrusion based
  11.4.2 Inkjet-based
  11.4.3 Laser-assisted
  11.4.4 Others
 11.5 Historic and Forecasted Market Size By Application
  11.5.1 Tissue Engineering
  11.5.2 Regenerative Medicine
  11.5.3 Organ & Drug Printing
  11.5.4 Toxicology Screening
  11.5.5 Others
 11.6 Historic and Forecasted Market Size By End Users
  11.6.1 Research Organizations & Academic Institutes
  11.6.2 Biopharmaceutical companies
  11.6.3 Hospitals
 11.7 Historic and Forecast Market Size by Country
  11.7.1 Germany
  11.7.2 U.K.
  11.7.3 France
  11.7.4 Italy
  11.7.5 Russia
  11.7.6 Spain
  11.7.7 Rest of Europe

Chapter 12: Asia-Pacific 3D Bioprinting Market Analysis, Insights and Forecast, 2016-2028
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Technology
  12.4.1 Extrusion based
  12.4.2 Inkjet-based
  12.4.3 Laser-assisted
  12.4.4 Others
 12.5 Historic and Forecasted Market Size By Application
  12.5.1 Tissue Engineering
  12.5.2 Regenerative Medicine
  12.5.3 Organ & Drug Printing
  12.5.4 Toxicology Screening
  12.5.5 Others
 12.6 Historic and Forecasted Market Size By End Users
  12.6.1 Research Organizations & Academic Institutes
  12.6.2 Biopharmaceutical companies
  12.6.3 Hospitals
 12.7 Historic and Forecast Market Size by Country
  12.7.1 China
  12.7.2 India
  12.7.3 Japan
  12.7.4 Singapore
  12.7.5 Australia
  12.7.6 New Zealand
  12.7.7 Rest of APAC

Chapter 13: Middle East & Africa 3D Bioprinting Market Analysis, Insights and Forecast, 2016-2028
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Technology
  13.4.1 Extrusion based
  13.4.2 Inkjet-based
  13.4.3 Laser-assisted
  13.4.4 Others
 13.5 Historic and Forecasted Market Size By Application
  13.5.1 Tissue Engineering
  13.5.2 Regenerative Medicine
  13.5.3 Organ & Drug Printing
  13.5.4 Toxicology Screening
  13.5.5 Others
 13.6 Historic and Forecasted Market Size By End Users
  13.6.1 Research Organizations & Academic Institutes
  13.6.2 Biopharmaceutical companies
  13.6.3 Hospitals
 13.7 Historic and Forecast Market Size by Country
  13.7.1 Turkey
  13.7.2 Saudi Arabia
  13.7.3 Iran
  13.7.4 UAE
  13.7.5 Africa
  13.7.6 Rest of MEA

Chapter 14: South America 3D Bioprinting Market Analysis, Insights and Forecast, 2016-2028
 14.1 Key Market Trends, Growth Factors and Opportunities
 14.2 Impact of Covid-19
 14.3 Key Players
 14.4 Key Market Trends, Growth Factors and Opportunities
 14.4 Historic and Forecasted Market Size By Technology
  14.4.1 Extrusion based
  14.4.2 Inkjet-based
  14.4.3 Laser-assisted
  14.4.4 Others
 14.5 Historic and Forecasted Market Size By Application
  14.5.1 Tissue Engineering
  14.5.2 Regenerative Medicine
  14.5.3 Organ & Drug Printing
  14.5.4 Toxicology Screening
  14.5.5 Others
 14.6 Historic and Forecasted Market Size By End Users
  14.6.1 Research Organizations & Academic Institutes
  14.6.2 Biopharmaceutical companies
  14.6.3 Hospitals
 14.7 Historic and Forecast Market Size by Country
  14.7.1 Brazil
  14.7.2 Argentina
  14.7.3 Rest of SA

Chapter 15 Investment Analysis

Chapter 16 Analyst Viewpoint and Conclusion

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. 3D BIOPRINTING MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. 3D BIOPRINTING MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. 3D BIOPRINTING MARKET COMPETITIVE RIVALRY
TABLE 005. 3D BIOPRINTING MARKET THREAT OF NEW ENTRANTS
TABLE 006. 3D BIOPRINTING MARKET THREAT OF SUBSTITUTES
TABLE 007. 3D BIOPRINTING MARKET BY TECHNOLOGY
TABLE 008. EXTRUSION BASED MARKET OVERVIEW (2016-2028)
TABLE 009. INKJET-BASED MARKET OVERVIEW (2016-2028)
TABLE 010. LASER-ASSISTED MARKET OVERVIEW (2016-2028)
TABLE 011. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 012. 3D BIOPRINTING MARKET BY APPLICATION
TABLE 013. TISSUE ENGINEERING MARKET OVERVIEW (2016-2028)
TABLE 014. REGENERATIVE MEDICINE MARKET OVERVIEW (2016-2028)
TABLE 015. ORGAN & DRUG PRINTING MARKET OVERVIEW (2016-2028)
TABLE 016. TOXICOLOGY SCREENING MARKET OVERVIEW (2016-2028)
TABLE 017. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 018. 3D BIOPRINTING MARKET BY END USERS
TABLE 019. RESEARCH ORGANIZATIONS & ACADEMIC INSTITUTES MARKET OVERVIEW (2016-2028)
TABLE 020. BIOPHARMACEUTICAL COMPANIES MARKET OVERVIEW (2016-2028)
TABLE 021. HOSPITALS MARKET OVERVIEW (2016-2028)
TABLE 022. NORTH AMERICA 3D BIOPRINTING MARKET, BY TECHNOLOGY (2016-2028)
TABLE 023. NORTH AMERICA 3D BIOPRINTING MARKET, BY APPLICATION (2016-2028)
TABLE 024. NORTH AMERICA 3D BIOPRINTING MARKET, BY END USERS (2016-2028)
TABLE 025. N 3D BIOPRINTING MARKET, BY COUNTRY (2016-2028)
TABLE 026. EUROPE 3D BIOPRINTING MARKET, BY TECHNOLOGY (2016-2028)
TABLE 027. EUROPE 3D BIOPRINTING MARKET, BY APPLICATION (2016-2028)
TABLE 028. EUROPE 3D BIOPRINTING MARKET, BY END USERS (2016-2028)
TABLE 029. 3D BIOPRINTING MARKET, BY COUNTRY (2016-2028)
TABLE 030. ASIA PACIFIC 3D BIOPRINTING MARKET, BY TECHNOLOGY (2016-2028)
TABLE 031. ASIA PACIFIC 3D BIOPRINTING MARKET, BY APPLICATION (2016-2028)
TABLE 032. ASIA PACIFIC 3D BIOPRINTING MARKET, BY END USERS (2016-2028)
TABLE 033. 3D BIOPRINTING MARKET, BY COUNTRY (2016-2028)
TABLE 034. MIDDLE EAST & AFRICA 3D BIOPRINTING MARKET, BY TECHNOLOGY (2016-2028)
TABLE 035. MIDDLE EAST & AFRICA 3D BIOPRINTING MARKET, BY APPLICATION (2016-2028)
TABLE 036. MIDDLE EAST & AFRICA 3D BIOPRINTING MARKET, BY END USERS (2016-2028)
TABLE 037. 3D BIOPRINTING MARKET, BY COUNTRY (2016-2028)
TABLE 038. SOUTH AMERICA 3D BIOPRINTING MARKET, BY TECHNOLOGY (2016-2028)
TABLE 039. SOUTH AMERICA 3D BIOPRINTING MARKET, BY APPLICATION (2016-2028)
TABLE 040. SOUTH AMERICA 3D BIOPRINTING MARKET, BY END USERS (2016-2028)
TABLE 041. 3D BIOPRINTING MARKET, BY COUNTRY (2016-2028)
TABLE 042. ARCAM AB (GE COMPANY): SNAPSHOT
TABLE 043. ARCAM AB (GE COMPANY): BUSINESS PERFORMANCE
TABLE 044. ARCAM AB (GE COMPANY): PRODUCT PORTFOLIO
TABLE 045. ARCAM AB (GE COMPANY): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 045. CYFUSE BIOMEDICAL KK: SNAPSHOT
TABLE 046. CYFUSE BIOMEDICAL KK: BUSINESS PERFORMANCE
TABLE 047. CYFUSE BIOMEDICAL KK: PRODUCT PORTFOLIO
TABLE 048. CYFUSE BIOMEDICAL KK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 048. REGENHU SA: SNAPSHOT
TABLE 049. REGENHU SA: BUSINESS PERFORMANCE
TABLE 050. REGENHU SA: PRODUCT PORTFOLIO
TABLE 051. REGENHU SA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 051. 3D SYSTEMS CORPORATION: SNAPSHOT
TABLE 052. 3D SYSTEMS CORPORATION: BUSINESS PERFORMANCE
TABLE 053. 3D SYSTEMS CORPORATION: PRODUCT PORTFOLIO
TABLE 054. 3D SYSTEMS CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 054. ASPECT BIOSYSTEMS LTD: SNAPSHOT
TABLE 055. ASPECT BIOSYSTEMS LTD: BUSINESS PERFORMANCE
TABLE 056. ASPECT BIOSYSTEMS LTD: PRODUCT PORTFOLIO
TABLE 057. ASPECT BIOSYSTEMS LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 057. GESIM GMBH: SNAPSHOT
TABLE 058. GESIM GMBH: BUSINESS PERFORMANCE
TABLE 059. GESIM GMBH: PRODUCT PORTFOLIO
TABLE 060. GESIM GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 060. CELLINK AB: SNAPSHOT
TABLE 061. CELLINK AB: BUSINESS PERFORMANCE
TABLE 062. CELLINK AB: PRODUCT PORTFOLIO
TABLE 063. CELLINK AB: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 063. ENVISION TEC GMBH: SNAPSHOT
TABLE 064. ENVISION TEC GMBH: BUSINESS PERFORMANCE
TABLE 065. ENVISION TEC GMBH: PRODUCT PORTFOLIO
TABLE 066. ENVISION TEC GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 066. ORGANOVO HOLDINGS INC.: SNAPSHOT
TABLE 067. ORGANOVO HOLDINGS INC.: BUSINESS PERFORMANCE
TABLE 068. ORGANOVO HOLDINGS INC.: PRODUCT PORTFOLIO
TABLE 069. ORGANOVO HOLDINGS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 069. STRATASYS LTD: SNAPSHOT
TABLE 070. STRATASYS LTD: BUSINESS PERFORMANCE
TABLE 071. STRATASYS LTD: PRODUCT PORTFOLIO
TABLE 072. STRATASYS LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 072. REGEMAT 3D: SNAPSHOT
TABLE 073. REGEMAT 3D: BUSINESS PERFORMANCE
TABLE 074. REGEMAT 3D: PRODUCT PORTFOLIO
TABLE 075. REGEMAT 3D: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 075. 3D BIOPRINTING SOLUTIONS: SNAPSHOT
TABLE 076. 3D BIOPRINTING SOLUTIONS: BUSINESS PERFORMANCE
TABLE 077. 3D BIOPRINTING SOLUTIONS: PRODUCT PORTFOLIO
TABLE 078. 3D BIOPRINTING SOLUTIONS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 078. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 079. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 080. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 081. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. 3D BIOPRINTING MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. 3D BIOPRINTING MARKET OVERVIEW BY TECHNOLOGY
FIGURE 012. EXTRUSION BASED MARKET OVERVIEW (2016-2028)
FIGURE 013. INKJET-BASED MARKET OVERVIEW (2016-2028)
FIGURE 014. LASER-ASSISTED MARKET OVERVIEW (2016-2028)
FIGURE 015. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 016. 3D BIOPRINTING MARKET OVERVIEW BY APPLICATION
FIGURE 017. TISSUE ENGINEERING MARKET OVERVIEW (2016-2028)
FIGURE 018. REGENERATIVE MEDICINE MARKET OVERVIEW (2016-2028)
FIGURE 019. ORGAN & DRUG PRINTING MARKET OVERVIEW (2016-2028)
FIGURE 020. TOXICOLOGY SCREENING MARKET OVERVIEW (2016-2028)
FIGURE 021. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 022. 3D BIOPRINTING MARKET OVERVIEW BY END USERS
FIGURE 023. RESEARCH ORGANIZATIONS & ACADEMIC INSTITUTES MARKET OVERVIEW (2016-2028)
FIGURE 024. BIOPHARMACEUTICAL COMPANIES MARKET OVERVIEW (2016-2028)
FIGURE 025. HOSPITALS MARKET OVERVIEW (2016-2028)
FIGURE 026. NORTH AMERICA 3D BIOPRINTING MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 027. EUROPE 3D BIOPRINTING MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 028. ASIA PACIFIC 3D BIOPRINTING MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 029. MIDDLE EAST & AFRICA 3D BIOPRINTING MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 030. SOUTH AMERICA 3D BIOPRINTING MARKET OVERVIEW BY COUNTRY (2016-2028)